SGLT2 Inhibitors

Global SGLT2 Inhibitors Market to Reach ## by 2034

The global market for SGLT2 Inhibitors estimated at ## in the year 2024, is expected to reach ## by 2034, growing at a CAGR of 0.0% over the analysis period 2024-2034.

Global SGLT2 Inhibitors Market – Key Trends & Drivers Summarized

Is Expanding Therapeutic Scope Transforming the Market Landscape for SGLT2 Inhibitors?

The global market for SGLT2 inhibitors is undergoing a major transformation, moving far beyond its original focus on glycemic control in type 2 diabetes. What began as a novel class of antidiabetic agents has now evolved into a cornerstone therapy in cardio-renal-metabolic care. Clinical trials over the last few years have consistently demonstrated that SGLT2 inhibitors such as empagliflozin, dapagliflozin, and canagliflozin deliver significant cardiovascular and renal protective effects independent of their blood glucose-lowering abilities. As a result, these drugs are increasingly being prescribed not only for type 2 diabetes but also for heart failure with reduced ejection fraction (HFrEF), chronic kidney disease (CKD), and more recently, heart failure with preserved ejection fraction (HFpEF). Regulatory bodies across the globe have responded by expanding approved indications, which is dramatically broadening the patient population eligible for these therapies. This shift marks a key inflection point in the market, as endocrinologists, cardiologists, and nephrologists begin to co-manage patients using a shared pharmacological tool. The repositioning of SGLT2 inhibitors as multi-disease agents is significantly boosting their clinical value, healthcare system relevance, and long-term market sustainability.

Can Real-World Evidence and Guideline Inclusion Propel Mainstream Adoption?

One of the most powerful drivers behind the widespread adoption of SGLT2 inhibitors is the robust body of real-world evidence and major endorsements from global clinical guidelines. Organizations such as the American Diabetes Association (ADA), European Society of Cardiology (ESC), Kidney Disease: Improving Global Outcomes (KDIGO), and the American College of Cardiology (ACC) have rapidly incorporated SGLT2 inhibitors into their treatment protocols—not only for glucose control but as first-line therapy for heart failure and CKD, even in patients without diabetes. This cross-specialty acceptance is propelling greater confidence among prescribers, leading to earlier initiation and broader use across patient profiles. Additionally, large-scale outcomes studies continue to reinforce the drug class’s benefits in reducing hospitalization for heart failure, slowing progression of kidney disease, and lowering cardiovascular mortality. These findings have been instrumental in convincing payers and formulary committees to expand reimbursement, especially in markets with value-based healthcare models. The growing repository of post-marketing surveillance data and patient registries is further validating the drugs` safety profiles, helping to dispel concerns around side effects such as diabetic ketoacidosis or genitourinary infections. This strong evidence-based foundation is making SGLT2 inhibitors one of the most rapidly adopted therapeutic classes in recent years.

Are Market Dynamics and Competitive Expansion Driving Innovation in SGLT2-Based Therapies?

The commercial success of first-generation SGLT2 inhibitors has sparked a wave of R&D and competitive activity, with pharmaceutical companies racing to extend the clinical and market footprint of the drug class. The emergence of combination therapies—such as SGLT2 inhibitors paired with DPP-4 inhibitors or GLP-1 receptor agonists—is opening new avenues for integrated diabetes and metabolic disorder management. At the same time, next-generation molecules with dual or triple inhibitory activity (e.g., SGLT1/SGLT2 inhibitors) are being developed to enhance efficacy and expand therapeutic targets. Companies are also exploring novel delivery formats, extended-release formulations, and co-formulated pills to improve patient adherence and convenience. Competitive differentiation is becoming crucial as more players enter the space, particularly in generics and biosimilars as key patents begin to expire. In addition, strategic partnerships, licensing deals, and co-marketing arrangements are on the rise, as firms look to strengthen market positioning and regional access. Geographic expansion into underserved markets—particularly in Asia-Pacific, Latin America, and the Middle East—is another key strategy, enabled by growing awareness of chronic disease prevalence and improvements in diagnostic infrastructure. As the competitive field becomes more sophisticated, innovation and market agility are defining the next growth phase for the SGLT2 inhibitors category.

What’s Fueling the Rapid Growth of the SGLT2 Inhibitors Market?

The growth in the SGLT2 inhibitors market is driven by several factors directly tied to evolving clinical guidelines, expanding indications, and healthcare infrastructure trends. First, the shift from glucose-centric prescribing to a broader focus on cardiovascular and renal protection is significantly increasing the number of eligible patients. Second, strong support from international guidelines is driving adoption across multiple specialties, making these drugs a go-to therapy for cardiologists and nephrologists as well as endocrinologists. Third, the growing global burden of type 2 diabetes, heart failure, and chronic kidney disease is expanding the need for therapies that offer multi-organ protection and long-term outcomes. Fourth, pharmaceutical innovation is extending the life cycle of the drug class through combination therapies, expanded indications, and next-generation molecules. Fifth, improved physician awareness and education programs are encouraging earlier initiation and better adherence. Sixth, payer willingness to reimburse for SGLT2 inhibitors in high-risk patients is supporting access, especially in regions with value-based care models. Seventh, digital health integration is enabling better monitoring and long-term tracking of therapy outcomes, which is helping demonstrate real-world value. Lastly, growing patient demand for oral, once-daily therapies with proven protective benefits is reinforcing the class’s appeal in chronic disease management. Together, these drivers are establishing SGLT2 inhibitors as a foundational therapy in the global fight against cardio-renal-metabolic disorders.

SCOPE OF STUDY:

The report analyzes the SGLT2 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 39 Featured) -

• Astellas Pharma Inc.
• AstraZeneca
• Biocon Limited
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Chugai Pharmaceutical Co., Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Kissei Pharmaceutical Co. Ltd.
• Kowa Company Ltd.
• Lexicon Pharmaceuticals, Inc.
• Lexicon Pharmaceuticals, Inc.
• Lupin Limited
• Mankind Pharma Ltd
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Ono Pharmaceutical Co., Ltd.
• Pfizer
• Sanofi
• Sihuan Pharmaceutical Holdings Group Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd
• Taisho Pharmaceutical Holdings Co.
• TheracosBio, LLC
• Torrent Pharmaceuticals Ltd
• Youngene Therapeutics Inc. Ltd

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.